AscenZion Neuromodulation Co Pte Ltd (“AscenZion”) is a Singapore based company that specializes in non-invasive neuromodulation medical devices used for the treatment of chronic neurological and pyschiatric diseases such as Cerebral Palsy, Autism Spectrum Disorder, ADHD, Sleep disorders, Parkinson’s Disease, Cerebellar Ataxia, Alzheimer’s Disease and other Dementias, Ischemic Stroke, Neuromuscular Dystropy, Chronic pain and Constipation.
Our vision is to empower clients and their families to live life with a chronic disease triumphantly and rediscover hope for a better future. We provide safe, effective, and long-term sustainable treatment solutions via innovative, rigorous research-backed non-invasive neuromodulation medical devices that may help our clients regain functionality and cognitive abilities, recover lost dignity and enjoy an overall higher quality of life.
At AscenZion, we understand the various challenges that our clients and their families grapple with in the face of chronic neurological disorders, such as coping with physical and cognitive dysfunctions, emotional stress, caretaking burdens and financial difficulties due to mounting medical costs. There is no need to feel despair, helpless or hopeless.
AscenZion provides personalized solutions that are evidence-based, non-invasive and free from drugs’ side effects. All our treatments may be performed in the comforts of one’s own home, reducing multiple trips to medical institutions and increasing convenience for our clients, and most importantly, achieve revolutionary treatment outcomes.
First-generation Founder Mr Zhong Hua (left) and Chief Engineer Wang Shi Jun (right).
AscenZion Neuromodulation Co Pte Ltd (“AscenZion”) is a neuroscience research-intensive medical device innovator. We leverage on a 15-year bedrock foundation of cutting-edge research in non-invasive neuromodulation by our principal bioengineering partner Beijing Yiqi Biotechnology Co. Ltd (“YQ”), to develop AscenZion’s superior range of medical devices that caters for various treatment needs of our clients.
Our current strategic research partners include top Singapore hospitals such as the National Neuroscience Institute, Singapore General Hospital, National University Hospital, KK Women’s and Children’s Hospital,Changi General Hospital, the Institute of Mental Health and more.
AscenZion Neuromodulation obtained Singapore Health Science Authority approval to register Multi-channel Pulsed Current Stimulators, model AscenZ-IV , as a Class B Device for the treatment of Spasticity in Pediatric Cerebral Palsy.
YQ Multi-channel Pulsed Current Stimulators obtained the “New Utility” patent from China National Intellectual Property Administration.
Our clinical research paper on the combined effect of tPCS and TENS for the treatment of limb spasticity in severe CP children was successfully published in BMC pediatrics. https://doi.org/10.1186/s12887-021-02615-1/20
Establishment of our Singapore presence via the founding of AscenZion Neuromodulation Co.
Our corporate philanthropy arm, Guangzhou Yirui Charitable Foundation, celebrated our philanthropic efforts in supporting free rehabilitation using YQ’s medical devices for over 5000 severe cerebral palsy orphans in China since 2014.
YQ Multi-channel Pulsed Current Stimulators spanned over 500 medical institutions users in China.
YQ Multi-channel Pulsed Current Stimulators obtained “New Technological Design” Patent by China National Intellectual Property Administration.
YQ was awarded “Best Health Innovation project” in the medical device category, by the National Science and Technology Commission, Ministry of Health, China.
YQ was awarded “Special contribution prize” by the China State Sports Council.
YQ’s products was appointed as the official rehabilitation device for Chinese Olympic athletes in the 2012 London Olympics and was
YQ was awarded Gold medal for the “Most Innovative Therapeutic Device” category at the International Health Expo in Beijing, China.
Establishment of Beijing Yiqi Biotechnology Co. Ltd (“YQ”)
AscenZion Neuromodulation Co Pte Ltd (“AscenZion”) is a neuroscience research-intensive medical device innovator. We leverage on a 15-year bedrock foundation of cutting-edge research in non-invasive neuromodulation by our principal bioengineering partner Beijing Yiqi Biotechnology Co. Ltd (“YQ”), to develop AscenZion’s superior range of medical devices that caters for various treatment needs of our clients.
Our current strategic research partners include top Singapore hospitals such as the National Neuroscience Institute, Singapore General Hospital, National University Hospital, KK Women’s and Children’s Hospital,Changi General Hospital, the Institute of Mental Health and more.
Ascension Neurorehabilitation Co Pte Ltd (“Ascension”) is the Singapore-based affiliated company of Yiqi Biotechnology Group Ltd (“YQ”), an innovative, biomedical engineering and neuroscience focused medical device manufacturer in Beijing, China. YQ is deeply involved in the pioneering R&D of non-invasive neuromodulation technology for over 15 years with a niche in transcranial pulsed current stimulation technology.
Ascension Neurorehabilitation Co Pte Ltd (“Ascension”) is the Singapore-based affiliated company of Yiqi Biotechnology Group Ltd (“YQ”), an innovative, biomedical engineering and neuroscience focused medical device manufacturer in Beijing, China. YQ is deeply involved in the pioneering R&D of non-invasive neuromodulation technology for over 15 years with a niche in transcranial pulsed current stimulation technology.
Co-founder & Chief Technology Officer
CEO & Head of Research
AscenZion Neuromodulation obtained Singapore Health Science Authority approval to register Multi-channel Pulsed Current Stimulators, model AscenZ-IV , as a Class B Device for the treatment of Spasticity in Pediatric Cerebral Palsy.
YQ Multi-channel Pulsed Current Stimulators obtained the “New Utility” patent from China National Intellectual Property Administration.
Our clinical research paper on the combined effect of tPCS and TENS for the treatment of limb spasticity in severe CP children was successfully published in BMC pediatrics. https://doi.org/10.1186/s12887-021-02615-1/20
Establishment of our Singapore presence via the founding of AscenZion Neuromodulation Co.
Our corporate philanthropy arm, Guangzhou Yirui Charitable Foundation, celebrated our philanthropic efforts in supporting free rehabilitation using YQ’s medical devices for over 5000 severe cerebral palsy orphans in China since 2014.
YQ Multi-channel Pulsed Current Stimulators spanned over 500 medical institutions users in China.
YQ Multi-channel Pulsed Current Stimulators obtained “New Technological Design” Patent by China National Intellectual Property Administration.
YQ was awarded “Best Health Innovation project” in the medical device category, by the National Science and Technology Commission, Ministry of Health, China.
YQ was awarded “Special contribution prize” by the China State Sports Council.
YQ’s products was appointed as the official rehabilitation device for Chinese Olympic athletes in the 2012 London Olympics and was
YQ was awarded Gold medal for the “Most Innovative Therapeutic Device” category at the International Health Expo in Beijing, China.
Establishment of Beijing Yiqi Biotechnology Co. Ltd (“YQ”)
AscenZion Neuromodulation Co Pte Ltd (“AscenZion”) is a neuroscience research-intensive medical device innovator. We leverage on a 15-year bedrock foundation of cutting-edge research in non-invasive neuromodulation by our principal bioengineering partner Beijing Yiqi Biotechnology Co. Ltd (“YQ”), to develop AscenZion’s superior range of medical devices that caters for various treatment needs of our clients.
Our current strategic research partners include top Singapore hospitals such as the National Neuroscience Institute, Singapore General Hospital, National University Hospital, KK Women’s and Children’s Hospital,Changi General Hospital, the Institute of Mental Health and more.
AscenZion Neuromodulation obtained Singapore Health Science Authority approval to register Multi-channel Pulsed Current Stimulators, model AscenZ-IV , as a Class B Device for the treatment of Spasticity in Pediatric Cerebral Palsy.
YQ Multi-channel Pulsed Current Stimulators obtained the “New Utility” patent from China National Intellectual Property Administration.
Our clinical research paper on the combined effect of tPCS and TENS for the treatment of limb spasticity in severe CP children was successfully published in BMC pediatrics. https://doi.org/10.1186/s12887-021-02615-1/20
Establishment of our Singapore presence via the founding of AscenZion Neuromodulation Co.
Our corporate philanthropy arm, Guangzhou Yirui Charitable Foundation, celebrated our philanthropic efforts in supporting free rehabilitation using YQ’s medical devices for over 5000 severe cerebral palsy orphans in China since 2014.
YQ Multi-channel Pulsed Current Stimulators spanned over 500 medical institutions users in China.
YQ Multi-channel Pulsed Current Stimulators obtained “New Technological Design” Patent by China National Intellectual Property Administration.
YQ was awarded “Best Health Innovation project” in the medical device category, by the National Science and Technology Commission, Ministry of Health, China.
YQ was awarded “Special contribution prize” by the China State Sports Council.
YQ’s products was appointed as the official rehabilitation device for Chinese Olympic athletes in the 2012 London Olympics and was
YQ was awarded Gold medal for the “Most Innovative Therapeutic Device” category at the International Health Expo in Beijing, China.
Establishment of Beijing Yiqi Biotechnology Co. Ltd (“YQ”)
AscenZion Neuromodulation Co Pte Ltd (“AscenZion”) is a neuroscience research-intensive medical device innovator. We leverage on a 15-year bedrock foundation of cutting-edge research in non-invasive neuromodulation by our principal bioengineering partner Beijing Yiqi Biotechnology Co. Ltd (“YQ”), to develop AscenZion’s superior range of medical devices that caters for various treatment needs of our clients.
Our current strategic research partners include top Singapore hospitals such as the National Neuroscience Institute, Singapore General Hospital, National University Hospital, KK Women’s and Children’s Hospital,Changi General Hospital, the Institute of Mental Health and more.
Ascension Neurorehabilitation Co Pte Ltd (“Ascension”) is the Singapore-based affiliated company of Yiqi Biotechnology Group Ltd (“YQ”), an innovative, biomedical engineering and neuroscience focused medical device manufacturer in Beijing, China. YQ is deeply involved in the pioneering R&D of non-invasive neuromodulation technology for over 15 years with a niche in transcranial pulsed current stimulation technology.
Ascension Neurorehabilitation Co Pte Ltd (“Ascension”) is the Singapore-based affiliated company of Yiqi Biotechnology Group Ltd (“YQ”), an innovative, biomedical engineering and neuroscience focused medical device manufacturer in Beijing, China. YQ is deeply involved in the pioneering R&D of non-invasive neuromodulation technology for over 15 years with a niche in transcranial pulsed current stimulation technology.
May you find us as your most value-adding and trustworthy partner as we journey with you in this life-changing experience.
© 2023 AscenZion Neuromodulation All rights reserved.
Zhong Bing assumes the role of Chief Technical Officer at AscenZion and plays a principal role in MedTech innovation of the company. He is also the President and CEO of Yiqi Biotechnology Group Ltd (“YIQI”) in China, the strategic and cornerstone R&D partner of AscenZion Neuromodulation.
Zhong Bing graduated with high distinctions in Electrical Engineering from the National University of Defense Technology, a top military college in China in 1999. He obtained his master’s degree in Computer Science at the University of California San Diego in 2003. He holds an EMBA from Shanghai Jiao Tong university.
Zhong Bing has further achieved advance professional certification in applied Artificial Intelligence and Machine Learning from the School of Computing, National University of Singapore
YIQI subsidiaries:-
Zhong Bing assumes the role of Chief Technical Officer at AscenZion and plays a principal role in MedTech innovation of the company. He is also the President and CEO of Yiqi Biotechnology Group Ltd (“YIQI”) in China, the strategic and cornerstone R&D partner of AscenZion Neuromodulation.
Zhong Bing graduated with high distinctions in Electrical Engineering from the National University of Defense Technology, a top military college in China in 1999. He obtained his master’s degree in Computer Science at the University of California San Diego in 2003. He holds an EMBA from Shanghai Jiao Tong university.
YIQI subsidiaries:-
Sandra Zhong is the founder and CEO of AscenZion Neuromodulation in
Singapore and the second-generation owner of YIQI Biotechnology Co. Ltd in China. YIQI was first established in Beijing in 2007, for the past 15 years Sandra has been actively involved in leading clinical research efforts of the company which included large multi-center, cross-country collaborative clinical trials with researchers and scientists in Singapore and China.
Sandra graduated from King’s College London with a Masters Degree in Applied Neuroscience and is trained in clinical research methods at Harvard TH Chan School of Public Health. As CEO, Sandra possesses deep knowledge of financial management and capital markets. Prior to her scientific career, she held senior positions as a banker at top financial institutions such as Credit Suisse and
Deutsche Bank for more than a decade.
In 2014, Sandra founded Yirui Charitable Foundation in China, a philanthropic organization that provided free rehabilitation services to abandoned children with Cerebral Palsy and Autism, after being deeply moved by the state of poverty, neglect and abuse of special needs children in Inner Mongolia. Over 8 years, Yirui Charitable Foundation grew significantly to encompass a network of 15 charitable rehabilitation centers across China, serving more than 5000 severely disabled orphans and trained more than 300 rehabilitation specialists.
Sandra Zhong is the founder and CEO of AscenZion Neuromodulation in
Singapore and the second-generation owner of YIQI Biotechnology Co. Ltd in China. YIQI was first established in Beijing in 2007, for the past 15 years Sandra has been actively involved in leading clinical research efforts of the company which included large multi-center, cross-country collaborative clinical trials with researchers and scientists in Singapore and China.
Sandra graduated from King’s College London with a Masters Degree in Applied Neuroscience and is trained in clinical research methods at Harvard TH Chan School of Public Health. As CEO, Sandra possesses deep knowledge of financial management and capital markets. Prior to her scientific career, she held senior positions as a banker at top financial institutions such as Credit Suisse and
Deutsche Bank for more than a decade.
In 2014, Sandra founded Yirui Charitable Foundation in China, a philanthropic organization that provided free rehabilitation services to abandoned children with Cerebral Palsy and Autism, after being deeply moved by the state of poverty, neglect and abuse of special needs children in Inner Mongolia. Over 8 years, Yirui Charitable Foundation grew significantly to encompass a network of 15 charitable rehabilitation centers across China, serving more than 5000 severely disabled orphans and trained more than 300 rehabilitation specialists.
Ada Kong has over 18 years of experience in medical devices and pharmaceutical sales, working with global companies such as Wyeth, Novartis and Li & Fung Asia (pharmaceuticals). She has extensive leadership experience throughout the entire product distribution value chain, from developing client-focused solutions to Marketing, Sales and Business strategy.
She holds a BSc in Biotechnology from Macquarie University, Sydney, Australia. She is also an avid parent volunteer at her church’s program for vulnerable and special needs kids.
Ada began her career as a microbiologist at Tan Tock Seng Hospital in Singapore in anti-infectives. From 2004-2008, Ada worked at Wyeth (Singapore) as a product specialist. During her 4 years with Wyeth, Ada was consistently awarded Best Sales Manager for her outstanding performance. From 2008-2020, Ada worked at Novartis (Singapore) as a Senior Sales Team Leader for the central nervous system specialists’ group. In the following 12 years, she built a strong network with top neurologists in Singapore and was consistently awarded Top Salesperson, Best Detailer, Novartis Outstanding Performer and Early Eagle Award for her strong performance in sales channel distribution.
Ada joined AscenZion in early 2021 with great expectations to revolutionize the chronic neurological diseases market with breakthrough solutions via non-invasive neuromodulation.
Ada Kong has over 18 years of experience in medical devices and pharmaceutical sales, working with global companies such as Wyeth, Novartis and Li & Fung Asia (pharmaceuticals). She has extensive leadership experience throughout the entire product distribution value chain, from developing client-focused solutions to Marketing, Sales and Business strategy.
She holds a BSc in Biotechnology from Macquarie University, Sydney, Australia. She is also an avid parent volunteer at her church’s program for vulnerable and special needs kids.
Ada began her career as a microbiologist at Tan Tock Seng Hospital in Singapore in anti-infectives. From 2004-2008, Ada worked at Wyeth (Singapore) as a product specialist. During her 4 years with Wyeth, Ada was consistently awarded Best Sales Manager for her outstanding performance. From 2008-2020, Ada worked at Novartis (Singapore) as a Senior Sales Team Leader for the central nervous system specialists’ group. In the following 12 years, she built a strong network with top neurologists in Singapore and was consistently awarded Top Salesperson, Best Detailer, Novartis Outstanding Performer and Early Eagle Award for her strong performance in sales channel distribution.
Ada joined AscenZion in early 2021 with great expectations to revolutionize the chronic neurological diseases market with breakthrough solutions via non-invasive neuromodulation.